News
Orca-T, an investigational allogeneic T-cell immunotherapy, improved cGVHD-free survival compared with allo-HSCT in patients with acute leukemia or MDS in the phase 3 Precision-T trial (NCT05316701).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback